ONL Therapeutics, a past New Enterprise Forum Showcase Presenter, has received a crucial orphan-drug designation from the U.S. Food and Drug Administration for its lead compound which is used to limit the damage caused to patients who suffer retinal detachments. Even successful retinal reattachments often result in impaired vision. Trials have shown that ONL's drug protects photoreceptors and is used to limit the damage caused to patients. Congratulations to ONL on this important milestone!
You can learn more at www.onltherapeutics.com.